Comparison of PEG-Intron 1.5microg/Kg/Wk plus REBETOL vs PEG-Intron 1microg/kg/wk plus REBETOL vs PEGASYS 180microg/Wk plus COPEGUS in previously untreated adult subjects with chronic hepatitis C infected with genotype 1

Trial Profile

Comparison of PEG-Intron 1.5microg/Kg/Wk plus REBETOL vs PEG-Intron 1microg/kg/wk plus REBETOL vs PEGASYS 180microg/Wk plus COPEGUS in previously untreated adult subjects with chronic hepatitis C infected with genotype 1

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IDEAL
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 03 Nov 2009 Actual patient number changed from 3070 to 4469 as reported by ClinicalTrials.gov.
    • 06 Aug 2009 Results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top